US-based pharmaceutical company Eli Lilly and Company (NYSE: LLY) announced on Thursday that will expand its manufacturing facility in Kenosha County, Wisconsin which was acquired earlier this year.

The planned USD3bn expansion is intended to extend the company's global parenteral (injectable) product manufacturing network, helping to meet increasing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas.

Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location. Construction is planned to commence in 2025.

The acquisition, expansion and additional purchases of land and the adjacent warehouse brings Lilly's total planned investment in Wisconsin to USD4bn. The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across various therapeutic areas.

Lilly said that it will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production. New highly skilled jobs at the site will include operators, technicians, engineers and scientists -- in addition to more than 2,000 construction jobs during the expansion project's construction.